Keyphrases
Breast Cancer
69%
Triple-negative Breast Cancer
51%
Metastatic Breast Cancer
51%
Tumor
39%
Endocrine Therapy
30%
Human Epidermal Growth Factor Receptor 2 (HER2)
25%
Aromatase Inhibitors
24%
Fulvestrant
23%
Estrogen Receptor
23%
Postmenopausal Women
21%
Chemotherapy
20%
Patient-derived Xenograft
20%
Estrogen Receptor-positive Breast Cancer
19%
Neoadjuvant Endocrine Therapy
19%
Neoadjuvant
17%
Phase II Trial
17%
Estrogen
16%
Cyclin-dependent Kinase 4/6 Inhibitors
16%
Confidence Interval
15%
Breast Cancer Patients
15%
Pathological Complete Response
14%
Circulating Tumor DNA (ctDNA)
14%
Estrogen Receptor 1 (ESR1)
14%
Cyclin-dependent Kinase 4 (CDK4)
13%
Palbociclib
13%
ER +
13%
Clinical Trials
13%
Carboplatin
13%
Ki-67
12%
HER2-positive
12%
Hormone Receptor-positive
12%
Phase II Study
11%
Neoadjuvant Chemotherapy
11%
Neratinib
11%
HER2-negative Breast Cancer
11%
Estrogen Receptor-positive
11%
Randomized Phase II Trial
10%
Advanced Breast Cancer
10%
Overall Survival
10%
Progression-free Survival
10%
Trastuzumab
9%
Anastrozole
9%
Estrogen Receptor-positive Metastatic Breast Cancer
9%
Targeted Therapy
9%
Resistance Mechanisms
9%
HER2 mutation
8%
Mammalian Target of Rapamycin (mTOR)
8%
PIK3CA mutation
8%
Targeted Treatment
8%
Breast Cancer Treatment
8%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
79%
Metastatic Breast Cancer
63%
Neoplasm
45%
Triple Negative Breast Cancer
29%
Estrogen Receptor
26%
Cyclin Dependent Kinase 4
24%
Endocrine Therapy
24%
Fulvestrant
23%
Malignant Neoplasm
20%
Chemotherapy
20%
Hormone Receptor
20%
Diseases
19%
Aromatase Inhibitor
17%
Progression Free Survival
17%
Palbociclib
16%
Clinical Trial
16%
Phase II Trials
14%
Carboplatin
13%
Neratinib
11%
Biological Marker
11%
Estrogen Receptor Positive Breast Cancer
11%
Gamma Urogastrone
10%
Overall Survival
10%
Tumor Growth
10%
Circulating Tumor DNA
10%
Epidermal Growth Factor Receptor 2
9%
Cyclin Dependent Kinase 6
9%
Anastrozole
8%
Trastuzumab
8%
Temsirolimus
8%
Pharmacokinetics
7%
Epidermal Growth Factor Receptor
7%
Bortezomib
7%
Phosphatidylinositol 3 Kinase
7%
Paclitaxel
7%
Maximum Tolerated Dose
7%
Adverse Event
7%
Solid Malignant Neoplasm
6%
Monotherapy
6%
Irinotecan
6%
Doxorubicin
6%
Aromatase
6%
Gemcitabine
5%
Neutropenia
5%
Metastasis
5%
Letrozole
5%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
5%
Disease Exacerbation
5%
Recurrent Disease
5%
Medicine and Dentistry
Breast Cancer
100%
Hormone Therapy
42%
Metastatic Breast Cancer
42%
Neoplasm
41%
Triple Negative Breast Cancer
37%
Estrogen Receptor
27%
Aromatase Inhibitor
20%
Malignant Neoplasm
18%
Clinical Trial
18%
Diseases
18%
Estrogen Receptor Positive Breast Cancer
16%
Cyclin-Dependent Kinase 4
13%
Neoadjuvant Chemotherapy
12%
Biological Marker
11%
Circulating Tumor DNA
11%
Hormone Receptor
10%
Phase II Trials
10%
Targeted Therapy
10%
Oncology
10%
Treatment Response
9%
Palbociclib
9%
Xenograft
9%
Aromatase
8%
Carboplatin
8%
Anastrozole
8%
Postmenopause
8%
Recurrent Disease
8%
Overall Survival
7%
Fulvestrant
7%
Progression Free Survival
7%
Metastatic Carcinoma
7%
Cancer
6%
Progesterone Receptor
6%
Neratinib
6%
Cell Signaling Pathway
6%
CDK4/6 Inhibitor
5%
Adjuvant Chemotherapy
5%
Neoadjuvant Therapy
5%
Clinical Stage
5%
Phosphoinositide 3-Kinase
5%
Letrozole
5%
Mammalian Target of Rapamycin
5%
Tumor Progression
5%
Circulating Tumor Cell
5%
Cancer Cell
5%
Programmed Cell Death
5%
